US › Healthcare

Benitec Biopharma Inc. (BNTC)

US · Healthcare · Biotechnology

$8.11-4.14%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$-833,044

Revenue YoY

-249.8%

Net profit

$-12.8M

EPS

$-0.26

EPS estimate

$-0.26

EPS came in at -0.26 against a street estimate of -0.26 — a beat of 0.0%.

Key statistics

Market cap

$289.2M

Forward P/E

0.0

P/B

1.94

Book value

$5.14

EPS (TTM)

$-0.94

52-week high

$16.76

52-week low

$8.25

50-day MA

$11.45

200-day MA

$11.77

Beta

0.25

Analyst view

Analysts rate Benitec Biopharma Inc. a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $24.33.

Shareholding

Insiders

2.51%

Institutions

96.02%

Largest institutional holders

Fund	Stake
Suvretta Capital Management, LLC	33.11%
Nantahala Capital Management, LLC	8.53%
HHG PLC	8.25%
Jupiter Topco LLC	7.11%
Franklin Templeton Inc	6.92%
Adage Capital Partners Gp LLC	6.08%
RA Capital Management, LLC	5.30%
BlackRock Inc	4.03%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Benitec Biopharma Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.